Multiple Myeloma Hub

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The session covered mechanisms of resistance with BCMA-targeted therapies; the impact of prior exposure to BCMA-directed therapies; the main differences between BCMA-directed antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies in terms of access, logistics, and toxicity profiles; and how dosing schedules can be adapted to optimize efficacy while limiting toxicity. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment paradigm. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies.In this presentation, Cook examined how populations enrolled in pivotal trials of BCMA-directed therapies compare with patients treated in routine clinical practice. Key differences were highlighted, including age, performance status, comorbidities, and prior treatment exposure. Cook presented data for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, focusing on efficacy and safety outcomes in real-world populations as well as the impact of prior BCMA exposure on response and durability of response. Real-world experience with adverse events, particularly infections and ocular complications, was also discussed, as were the implications of these findings for treatment sequencing as BCMA-directed therapies move into earlier lines of therapy.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Marc-Andrea Bärtsch, Heidelberg University Hospital, DE, delivered a presentation on the current applications of BCMA-directed therapies in multiple myeloma (MM) and the evolving clinical landscape. In this presentation, Bärtsch discussed the rationale for targeting BCMA in MM and reviewed pivotal clinical trial data supporting the approval of BCMA-directed therapies. Bärtsch outlined the mechanisms of action, clinical positioning, and key efficacy and safety findings for antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies, highlighting differences in availability, toxicity profiles, and durability of response across treatment modalities and lines of therapy.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM? In this interview, Mehmet Hakan Kocoglu discussed the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM, focusing on the key efficacy and safety data for this allogeneic BCMA-directed CAR T-cell therapy. This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor (CAR) T-cell therapy for eligible patients with multiple myeloma. The meeting opened with a presentation by Sagar Lonial and featured a discussion including Morie Gertz, Elena Zamagni, Meral Beksaç, and Sonia Zweegmann. During his presentation, Lonial provided an overview of approved and investigational CAR T-cell therapies for multiple myeloma, the CAR T-cell therapy treatment process, and multi-step treatment pathway. He explored barriers to treatment with CAR T-cell therapy, racial disparities in access to CAR T-cell therapy, and manufacturing and attrition considerations. He discussed potential strategies for improving access to CAR T-cell therapy for eligible patients, exploring patient selection and referral, optimizing the pre-CAR-T infusion process, use of CAR T-cell therapy in earlier lines of therapy, accelerated manufacturing, and allogeneic CAR T-cell therapies.This discussion topic is supported by Kite through Gilead Sciences Europe Ltd, who provided funding. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion. Hosted on Acast. See acast.com/privacy for more information.

Luciano Costa, a myeloma physician and researcher from the University of Alabama at Birmingham, dives into the fascinating long-term outcomes of the CARTITUDE-4 trial featuring cilta-cel for standard-risk relapsed/refractory multiple myeloma. He highlights how approximately 71% of patients remain progression-free at 30 months and discusses the promising implications for standard-risk patients. Costa also underscores the significant rates of minimal residual disease negativity and speculates that cilta-cel could become a one-time curative option for some, transforming treatment paradigms.

The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodotin, with a focus on strategies for managing ocular toxicity.During this interview, Popat discussed clinical experience using belantamab mafodotin for patients with relapsed or refractory multiple myeloma (RRMM), highlighting its mechanism as a B-cell maturation antigen (BCMA)-directed antibody–drug conjugate and the practical management of associated ocular toxicities. Popat emphasized key considerations in patient selection, treatment sequencing, and individualized dosing strategies to optimize outcomes while minimizing adverse events. The discussion also covered real-world approaches to monitoring, dose adjustment, and maintaining long-term treatment benefit without compromising safety or efficacy.This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Paul Richardson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, US. We asked about the clinical implications of findings from the phase III MIDAS trial (NCT04934475), which evaluated a measurable residual disease (MRD)-driven consolidation and maintenance strategy after induction with isatuximab + carfilzomib + lenalidomide + dexamethasone (Isa-KRd) in patients aged less than 66 years with newly diagnosed (ND), autologous stem-cell transplantation (ASCT)-eligible multiple myeloma (MM) (N = 791). The primary end point of the MIDAS trial was measurable residual disease (MRD)-negative status at 10−6 sensitivity before maintenance therapy. An additional aim was to evaluate the benefit of high-dose melphalan with ASCT (the current standard care) compared with Isa-KRd alone in patients who were MRD-negative at 10−5 sensitivity post induction. During this interview, Richardson discussed findings from the MIDAS trial, published by Perrot el al. in Blood and NEJM, and presented at the 2025 American Society of Clinical Oncology Annual Meeting. Hosted on Acast. See acast.com/privacy for more information.

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How might the clinical development of cereblon E3 ligase modulators (CELMoDs) impact the treatment paradigm for multiple myeloma (MM)? During this interview, Paul Richardson discussed the emerging role of CELMoDs in MM. Richardson reviewed the rationale for the development of these agents, what distinguishes them from traditional immunomodulatory agents (IMiDs), and the unmet needs they were designed to address in relapsed and refractory disease (RRMM). Richardson summarized clinical trial results with iberdomide and mezigdomide, highlighted their applications in high-risk and heavily pretreated patients, and emphasized their potential for use in earlier treatment settings and as maintenance therapy. Richardson also outlined ongoing phase III studies and novel combination strategies designed to optimize patient outcomes. This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.